BayWa's €2.7 Billion Shortfall Puts Restructuring on the Brink

The fate of German conglomerate BayWa’s multi-billion euro restructuring plan will be tested in the coming days. A €107 million payment from the sale of its Cefetra unit is due by April 30, but this sum is a mere fraction of the financial mountain the company must climb. The transaction is less a milestone and more a crucial signal to creditor banks whose continued patience is the plan's only foundation.

At the heart of the crisis is a staggering €2.7 billion financing gap. BayWa’s overarching goal is to raise four billion euros through asset sales. While cooperative owners have provided roughly €550 million via capital increases and loans, and €1.3 billion in divestments has been secured, the shortfall remains enormous. The incoming Cefetra funds—€45 million from the purchase price and €62 million from repaid shareholder loans—will reduce group bank debt by over €600 million. Yet this progress is dwarfed by the total required.

A central pillar of the original rescue concept has collapsed. The plan had banked on raising approximately €1.7 billion by 2028 from the gradual sale of its renewable energy subsidiary, BayWa r.e. That strategy unravelled after a U.S. policy shift. The "One Big Beautiful Bill Act," enacted in early 2025, slashed American subsidies for renewable energy. This directly impacts BayWa r.e., which sold over 530 megawatts of project capacity in the U.S. alone in 2024. The company now holds only a 35% stake following a February 2025 capital increase, with Energy Infrastructure Partners owning 65%. Management expects significantly lower total proceeds and has revised its EBITDA forecast for the unit downward, now targeting €150 million by 2030 instead of €230 million by 2028.

Parallel to this, the sale of New Zealand fruit grower T&G Global is underway, with Goldman Sachs advising since March 2026. T&G itself is not a distressed asset, having returned to profitability in 2024 with a net income of $16 million on revenue of $1.3 billion. However, the process is complicated by minority shareholder Joy Wing Mau Group, and even a successful deal yielding an estimated €300 million would do little to plug the billion-euro deficit.

Should investors sell immediately? Or is it worth buying BayWa?

For investors, the lack of clarity is compounded by a reporting void. The audited consolidated financial statements for 2025 are not expected until the fourth quarter of 2026, with PwC stepping down as auditor after the current fiscal year. On the governance front, three supervisory board members have departed, and a shareholder meeting to confirm their successors has yet to be scheduled.

Management has withdrawn its 2026 forecast and now targets an adjusted EBITDA of around €140 million for 2027. The broader restructuring aims to refocus the group on four core areas by end-2028, cutting approximately 1,300 jobs and reducing revenue to about €10 billion.

The stock price reflects the pervasive uncertainty. Shares trade at €14.00, roughly 17% below their 200-day moving average and down about 16% since the start of the year. The immediate future hinges on two key banks: DZ Bank and HVB. They must agree to extend a standstill agreement until autumn 2026. Without this extension, the StaRUG restructuring plan finalized in May 2025 loses its legal footing. Notably, BayWa has already written down 60% of a €220 million bond from Bavarian cooperative banks, indicating the pressure on creditors as well.

BayWa at a turning point? This analysis reveals what investors need to know now.

The €107 million Cefetra payment is the first tangible proof point that asset sales are proceeding. It is a bargaining chip designed to secure the vital bank approval. If it fails to convince them, the orderly restructuring of BayWa could rapidly descend into a summer of escalated financial pressure.

Ad

BayWa Stock: New Analysis - 19 April

Fresh BayWa information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BayWa analysis...

en | DE0005194005 | BAYWAS | boerse | 69198481 |